While pharmacologic interventions before cardiac arrest are impossible due to the unexpected occurrence of cardiac events in routine settings, our results offer an original concept that therapies targeting ALDH2 in treating cardiac arrest could be initiated at an early time window, e.g., during basic life support. This evidence concerns the gene ALDH2 and cardiac arrest.